If you liked this article you might like

Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain

The Market Is Not About Washington: Cramer's 'Mad Money' Recap (Wed 8/16/17)

Valeant Pharmaceuticals: Cramer's Top Takeaways

Valeant and Teva Share Similar Ambitions With Similar Pitfalls

Valeant Isn't Out of Trouble Yet, Debt Remains Difficult to Curb